Vascular endothelial growth factors and receptors: Anti-angiogenic therapy in the treatment of cancer

被引：180

作者：

Tugues, Sonia ^{[1
]}

Koch, Sina ^{[1
]}

Gualandi, Laura ^{[1
]}

Li, Xiujuan ^{[1
]}

Claesson-Welsh, Lena ^{[1
]}

机构：

[1] Uppsala Univ, Dept Immunol Genet & Pathol, Rudbeck Lab, S-75185 Uppsala, Sweden

来源：

MOLECULAR ASPECTS OF MEDICINE | 2011年 / 32卷 / 02期

关键词：

VEGFA; VEGF receptors; Neuropilin; Anti-angiogenesis; Sunitinib; Sorafenib; Bevacizumab; TYROSINE KINASE INHIBITOR; RENAL-CELL CARCINOMA; BEVACIZUMAB PLUS IRINOTECAN; LYMPH-NODE METASTASIS; TUMOR-GROWTH; HEPARIN-BINDING; BONE-MARROW; FACTOR-B; VEGF-A; ANTIANGIOGENIC THERAPY;

D O I：

10.1016/j.mam.2011.04.004

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Vascular endothelial growth factors (VEGFs) are critical regulators of vascular and lymphatic function during development, in health and in disease. There are five mammalian VEGF ligands and three VEGF receptor tyrosine kinases. In addition, several VEGF co-receptors that lack intrinsic catalytic activity, but that indirectly modulate the responsiveness to VEGF contribute to the final biological effect. This review describes the molecular features of VEGFs. VEGFRs and co-receptors with focus on their role in the treatment of cancer. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：88 / 111

页数：24

共 329 条

[1] Vascular endothelial growth factor-B-deficient mice display an atrial conduction defect [J].

Aase, K ;

von Euler, G ;

Li, X ;

Pontén, A ;

Thorén, P ;

Cao, R ;

Cao, Y ;

Olofsson, B ;

Gebre-Medhin, S ;

Pekny, M ;

Alitalo, K ;

Betsholtz, C ;

Eriksson, U .

CIRCULATION, 2001, 104 (03) :358-364

[2] Evading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy [J].

Abdollahi, Amir ;

Folkman, Judah .

DRUG RESISTANCE UPDATES, 2010, 13 (1-2) :16-28

[3] Molecular control of lymphatic metastasis [J].

Achen, Marc G. ;

Stacker, Steven A. .

LYMPHATIC CONTINUUM REVISITED, 2008, 1131 :225-234

[4] Heterogeneity of angiogenic activity in a human liposarcoma: A proposed mechanism for "no take" of human tumors in mice [J].

Achilles, EG ;

Fernandez, A ;

Allred, EN ;

Kisker, O ;

Udagawa, T ;

Beecken, WD ;

Flynn, E ;

Folkman, J .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (14) :1075-1081

[5] A strategy for the design of multiplex inhibitors for kinase-mediated signalling in angiogenesis [J].

Adams, J ;

Huang, P ;

Patrick, D .

CURRENT OPINION IN CHEMICAL BIOLOGY, 2002, 6 (04) :486-492

[6] Sorafenib (BAY 43-9006, Nexavar®), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature [J].

Adnane, Lila ;

Trail, Pamela A. ;

Taylor, Ian ;

Wilhelm, Scott M. .

REGULATORS AND EFFECTORS OF SMALL GTPASES: RAS FAMILY, 2006, 407 :597-+

[7] Impact of anti-angiogenic treatments on metastatic renal cell carcinoma [J].

Ainsworth, Nicola L. ;

Lee, Jean S. Z. ;

Eisen, Tim .

EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (12) :1793-1805

[8] Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth [J].

Albuquerque, Romulo J. C. ;

Hayashi, Takahiko ;

Cho, Won Gil ;

Kleinman, Mark E. ;

Dridi, Sami ;

Takeda, Atsunobu ;

Baffi, Judit Z. ;

Yamada, Kiyoshi ;

Kaneko, Hiroki ;

Green, Martha G. ;

Chappell, Joe ;

Wilting, Joerg ;

Weich, Herbert A. ;

Yamagami, Satoru ;

Amano, Shiro ;

Mizuki, Nobuhisa ;

Alexander, Jonathan S. ;

Peterson, Martha L. ;

Brekken, Rolf A. ;

Hirashima, Masanori ;

Capoor, Seema ;

Usui, Tomohiko ;

Ambati, Balamurali K. ;

Ambati, Jayakrishna .

NATURE MEDICINE, 2009, 15 (09) :1023-U74

[9] Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08 [J].

Allegra, Carmen J. ;

Yothers, Greg ;

O'Connell, Michael J. ;

Sharif, Saima ;

Petrelli, Nicholas J. ;

Colangelo, Linda H. ;

Atkins, James N. ;

Seay, Thomas E. ;

Fehrenbacher, Louis ;

Goldberg, Richard M. ;

O'Reilly, Seamus ;

Chu, Luis ;

Azar, Catherine A. ;

Lopa, Samia ;

Wolmark, Norman .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (01) :11-16

[10] Corneal avascularity is due to soluble VEGF receptor-1 [J].

Ambati, Balamurali K. ;

Nozaki, Miho ;

Singh, Nirbhai ;

Takeda, Atsunobu ;

Jani, Pooja D. ;

Suthar, Tushar ;

Albuquerque, Romulo J. C. ;

Richter, Elizabeth ;

Sakurai, Eiji ;

Newcomb, Michael T. ;

Kleinman, Mark E. ;

Caldwell, Ruth B. ;

Lin, Qing ;

Ogura, Yuichiro ;

Orecchia, Angela ;

Samuelson, Don A. ;

Agnew, Dalen W. ;

St. Leger, Judy ;

Green, W. Richard ;

Mahasreshti, Parameshwar J. ;

Curiel, David T. ;

Kwan, Donna ;

Marsh, Helene ;

Ikeda, Sakae ;

Leiper, Lucy J. ;

Collinson, J. Martin ;

Bogdanovich, Sasha ;

Khurana, Tejvir S. ;

Shibuya, Masabumi ;

Baldwin, Megan E. ;

Ferrara, Napoleone ;

Gerber, Hans-Peter ;

De Falco, Sandro ;

Witta, Jassir ;

Baffi, Judit Z. ;

Raisler, Brian J. ;

Ambati, Jayakrishna .

NATURE, 2006, 443 (7114) :993-997

← 1 2 3 4 5 6 7 8 9 10 →